COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.
DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I.
DE Cremoux P, et al. Among authors: spyratos f.
Anticancer Res. 2018 Mar;38(3):1485-1490. doi: 10.21873/anticanres.12375.
Anticancer Res. 2018.
PMID: 29491076
Clinical Trial.